Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in moderate to severe atopic dermatitis
NCT01552629Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ligelizumab in atopic dermatitis (AD), sponsored by Novartis. Started Jan 2012; status: completed.
02
Drugs
ligelizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01552629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01552629.